Applied DNA Sciences (NASDAQ:APDN) Lifted to “Sell” at StockNews.com

StockNews.com upgraded shares of Applied DNA Sciences (NASDAQ:APDN) to a sell rating in a report issued on Tuesday.

Separately, HC Wainwright cut their price target on Applied DNA Sciences from $7.00 to $1.50 and set a buy rating for the company in a report on Monday, June 10th.

Applied DNA Sciences Trading Up 2.9 %

Shares of APDN opened at $1.25 on Tuesday. The company has a market capitalization of $1.23 million, a price-to-earnings ratio of -0.07 and a beta of 0.37. The stock has a 50 day moving average of $1.04 and a 200 day moving average of $3.16. Applied DNA Sciences has a 12 month low of $0.31 and a 12 month high of $27.18.

Applied DNA Sciences (NASDAQ:APDN) last announced its quarterly earnings data on Thursday, August 8th. The technology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.64) by $1.11. Applied DNA Sciences had a negative return on equity of 138.41% and a negative net margin of 214.42%. The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $0.95 million. During the same period in the prior year, the company earned ($4.80) earnings per share. As a group, equities research analysts predict that Applied DNA Sciences will post -1.8 earnings per share for the current year.

Hedge Funds Weigh In On Applied DNA Sciences

A hedge fund recently raised its stake in Applied DNA Sciences stock. AMH Equity Ltd boosted its holdings in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) by 46.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 540,385 shares of the technology company’s stock after buying an additional 170,385 shares during the period. AMH Equity Ltd owned approximately 63.57% of Applied DNA Sciences worth $222,000 as of its most recent SEC filing. 22.22% of the stock is currently owned by institutional investors and hedge funds.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.